ReviewAnnals of hematology2014

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

Aristoteles Giagounidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.